Trump plans 100% tariffs on imported generic drugs. Here's what experts say.
Key Points:
- President Trump announced plans to impose tariffs of up to 200% on imported generic drugs starting in August 2028, aiming to encourage manufacturers to reshore production to the U.S.
- Health experts express skepticism that tariffs alone will prompt significant reshoring, citing high costs, infrastructure needs, and uncertain incentives for manufacturers to move operations domestically.
- The tariffs could lead to modest increases in generic drug prices due to manufacturers' slim margins, though competition and contracts may limit immediate consumer impact.
- There are concerns that some manufacturers might exit the U.S. market entirely in response to tariffs, potentially causing supply shortages and reduced availability of generic medications.
- Industry leaders emphasize the need for collaboration between policymakers and manufacturers to create sustainable frameworks that support domestic production and supply chain resilience.